home / stock / viri / viri news

VIRI News and Press, Virios Therapeutics Inc. From 05/09/24

Stock Information
Company Name: Virios Therapeutics Inc.
Stock Symbol: VIRI
Market: NASDAQ
Website: virios.com
Menu
VIRI VIRI Quote VIRI Short VIRI News VIRI Articles VIRI Message Board
Get VIRI Alerts

News, Short Squeeze, Breakout and More Instantly...
VIRI - Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

- Top-line results from the ongoing investigator-initiated Bateman Horne Center Long-COVID phase 2 featuring valacyclovir and celecoxib (IMC-2) expected in the second-half of 2024 - - Conference Call Today at 8:30 a.m. ET - ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Virios Therap...
VIRI - Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI ) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”...

VIRI - Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

- New patent would extend coverage and expand potential value of Virios’ antiviral pipeline globally – - Active Long-COVID characterized by immune dysfunction leading to recurrent herpesviruses reactivation - - Published data indicates increased Epstein-Barr ...

VIRI - Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) a...
VIRI - Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

ATLANTA, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FMȁ...

VIRI - Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID

- Placebo-Controlled Clinical Proof of Concept Data Expected in Mid-2024 - - Targeting Initiation of IMC-2 Phase 2 program in 2H 2024 - ATLANTA, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biot...

VIRI - Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on developing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FMȁ...
VIRI - Virios Therapeutics, Inc. (VIRI) Q3 2023 Earnings Call Transcript

2023-11-13 11:21:04 ET Virios Therapeutics, Inc. (VIRI) Q3 2023 Earnings Conference Call November 13, 2023, 8:30 a.m. ET Company Participants Greg Duncan - CEO Angela Walsh - SVP, Finance & Treasurer Mike Gendreau - CMO Conference Call Participants ...

VIRI - Virios Therapeutics GAAP EPS of -$0.06 beats by $0.04

2023-11-13 07:20:49 ET More on Virios Therapeutics Virios Therapeutics terminates at-the-market sales agreement Seeking Alpha’s Quant Rating on Virios Therapeutics Historical earnings data for Virios Therapeutics Financial information for Virios Therap...

VIRI - Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

- Conference Call Today at 8:30 a.m. ET - ATLANTA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases,...
Previous 10 Next 10